BSX · News · 20261102N

Product Pipeline Progress

BOSTON SCIENTIFIC CORP · 2026-11-02 · Importance 34 · Surprise 42

Boston Scientific and Blackstone Life Sciences announced a collaboration to co-fund development of Boston Scientific’s VITALYST temporary percutaneous transvalvular circulatory support system. The next-generation miniature heart pump is intended to increase cardiac output and improve blood flow to the brain and other vital organs. It is being developed for patients with acute myocardial infarction cardiogenic shock. The report describes this as the first product-development program the two organizations will co-fund.

Key facts

• On November 2, 2026, Boston Scientific announced positive six-month primary endpoint results from the SIMPLAAFY randomized controlled trial of the WATCHMAN FLX Pro LAAC Device. source
• In the SIMPLAAFY trial, both post-implant single-drug regimens achieved non-inferiority compared with dual anti-platelet therapy (DAPT). source
• In the SIMPLAAFY trial, the single-drug regimens resulted in less bleeding and equivalent ischemic stroke rates compared with DAPT. source
• The SIMPLAAFY trial evaluated aspirin alone and a reduced-dose anticoagulant as alternatives to DAPT after WATCHMAN FLX Pro implantation in patients with non-valvular atrial fibrillation. source